{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:16:24Z","timestamp":1788948984460,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Older patients with advanced-stage classical Hodgkin lymphoma (cHL) have inferior outcomes compared with younger patients, potentially due to comorbidities and frailty. This noncomparative phase 2 study enrolled patients aged \u226560 years with cHL unfit for conventional chemotherapy to receive frontline brentuximab vedotin (BV; 1.8 mg\/kg) with dacarbazine (DTIC; 375 mg\/m2) (part B) or nivolumab (part D; 3 mg\/kg). In parts B and D, 50% and 38% of patients, respectively, had \u22653 general comorbidities or \u22651 significant comorbidity. Of the 22 patients treated with BV-DTIC, 95% achieved objective response, and 64% achieved complete response (CR). With a median follow-up of 63.6 months, median duration of response (mDOR) was 46.0 months. Median progression-free survival (mPFS) was 47.2 months; median overall survival (mOS) was not reached. Of 21 patients treated with BV-nivolumab, 86% achieved objective response, and 67% achieved CR. With 51.6 months of median follow-up, mDOR, mPFS, and mOS were not reached. Ten patients (45%) with BV-DTIC and 16 patients (76%) with BV-nivolumab experienced grade \u22653 treatment-emergent adverse events; sensory peripheral neuropathy (PN; 27%) and neutropenia (9%) were most common with BV-DTIC, and increased lipase (24%), motor PN (19%), and sensory PN (19%) were most common with BV-nivolumab. Despite high median age, inclusion of patients aged \u226488 years, and frailty, these results demonstrate safety and promising durable efficacy of BV-DTIC and BV-nivolumab combinations as frontline treatment, suggesting potential alternatives for older patients with cHL unfit for initial conventional chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT01716806.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2022019536","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T23:14:45Z","timestamp":1699571685000},"page":"786-795","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1420-5563","authenticated-orcid":false,"given":"Jonathan W.","family":"Friedberg","sequence":"first","affiliation":[{"name":"1Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Bordoni","sequence":"additional","affiliation":[{"name":"2Georgia Cancer Specialists, Marietta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Patel-Donnelly","sequence":"additional","affiliation":[{"name":"3Virginia Cancer Specialists, Fairfax, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Larson","sequence":"additional","affiliation":[{"name":"4Minnesota Oncology PA, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"5Oncology and Hematology Associates of SW Virginia, Blacksburg, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Boccia","sequence":"additional","affiliation":[{"name":"6Center for Cancer and Blood Disorders, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian J. M.","family":"Cline","sequence":"additional","affiliation":[{"name":"7Texas Oncology, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrija","family":"Mamidipalli","sequence":"additional","affiliation":[{"name":"8Seagen Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Liu","sequence":"additional","affiliation":[{"name":"8Seagen Inc, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alev","family":"Akyol","sequence":"additional","affiliation":[{"name":"9Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-156X","authenticated-orcid":false,"given":"Christopher A.","family":"Yasenchak","sequence":"additional","affiliation":[{"name":"10Willamette Valley Cancer Institute and Research Center\/US Oncology Research, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10114","key":"2024022916375137800_bib1","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"2024022916375137800_bib2","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024022916375137800_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2024022916375137800_bib4","doi-asserted-by":"crossref","first-page":"725219","DOI":"10.1155\/2011\/725219","article-title":"Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States","volume":"2011","author":"Shenoy","year":"2011","journal-title":"Adv Hematol"},{"issue":"5","key":"2024022916375137800_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/CCO.0000000000000464","article-title":"Hodgkin lymphoma in elderly patients","volume":"30","author":"Borchmann","year":"2018","journal-title":"Curr Opin Oncol"},{"issue":"25","key":"2024022916375137800_bib6","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2024022916375137800_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"2024022916375137800_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.16525","article-title":"First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study","volume":"190","author":"Rodday","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"2024022916375137800_bib9","doi-asserted-by":"crossref","first-page":"e2128373","DOI":"10.1001\/jamanetworkopen.2021.28373","article-title":"Association of treatment intensity with survival in older patients with Hodgkin lymphoma","volume":"4","author":"Rodday","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2024022916375137800_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2023.01.014","article-title":"Characteristics and outcomes of older patients with classical Hodgkin lymphoma: an Australasian Lymphoma Alliance, and Lymphoma and Related Diseases registry study","volume":"23","author":"Goh","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"30","key":"2024022916375137800_bib11","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024022916375137800_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-136583","article-title":"Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients [abstract]","volume":"136","author":"Yasenchak","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2024022916375137800_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024022916375137800_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024022916375137800_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2024022916375137800_bib16","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2024022916375137800_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"2024022916375137800_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-4899-3115-3_8","volume-title":"Modelling Survival Data in Medical Research","author":"Collett","year":"1994","edition":"1st ed."},{"issue":"10","key":"2024022916375137800_bib19","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024022916375137800_bib20","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2024022916375137800_bib21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"28","key":"2024022916375137800_bib22","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024022916375137800_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024022916375137800_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2024022916375137800_bib25","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024022916375137800_bib26","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a\u00a0multicentre, multicohort, single-arm phase\u00a02 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024022916375137800_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"2024022916375137800_bib28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2024022916375137800_bib29","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"issue":"suppl 17","key":"2024022916375137800_bib30","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL) [abstract]","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024022916375137800_bib31","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"issue":"18","key":"2024022916375137800_bib32","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"}],"updated-by":[{"DOI":"10.1182\/blood.2024026833","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/9\/786\/2216690\/blood_bld-2022-019536-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/9\/786\/2216690\/blood_bld-2022-019536-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T11:38:13Z","timestamp":1709206693000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/9\/786\/498658\/Brentuximab-vedotin-with-dacarbazine-or-nivolumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,2,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022019536","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}